Skip to content
Website Logo
Website Logo
  • Home
  • About Us
  • Leadership
  • Clinical Trials
  • Our Practices
  • Contact Us
News & Events

News & Events

A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.

  • by Quality Cancer Care Alliance
  • August 7, 2017
  • Clinical Updates

BACKGROUND: Activation of the mitogen activated protein kinase pathway plays a pivotal role in cell proliferation and is frequently activated in endometrial cancer. We sought… A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.

QCCA Practice Earns NCQA Recognition

  • by Quality Cancer Care Alliance
  • June 22, 2017
  • In the News

Oncology Medical Home Pilot Sites Earn NCQA Recognition

  • « Previous
  • 1
  • …
  • 6
  • 7
  • 8
  • Home
  • About Us
  • Leadership
  • Clinical Trials
  • Our Practices
  • Contact Us
  • Privacy Policy
  • Statement of Non-Discrimination
  • Sitemap
Copyright 2022 Quality Cancer Care Alliance | Medical Website Design by Practis